GO
Loading...

Abbott Laboratories

More

  • Pops & Drops: Dell, True Religion... Tuesday, 13 May 2008 | 6:38 PM ET

    Following are the day’s biggest winners and losers. Find out why shares of Dell and Fluor popped while True Religion and Western Refining dropped

  • HP Drags on Dow; Yahoo Buoys Nasdaq Tuesday, 13 May 2008 | 5:11 PM ET

    Stocks declined Tuesday as investors expressed their disappointment in Wal-Mart's outlook, HP's deal and a slew of other news. Surprising resilience in retail sales, excluding autos, helped curb losses. The Nasdaq eked out a gain, led by Yahoo.

  • HP Drags on Dow; Icahn Buzz Boosts Yahoo Tuesday, 13 May 2008 | 3:08 PM ET

    Stocks declined Tuesday as investors juggled a mixed bag of news: Retail sales outside of the hard-hit auto sector showed suprising resilience, while a well-known analyst cut her outlook for big banks. Wal-Mart skidded after the discount giant posted decent results but issued a tepid outlook.

  • Study Shows Conflicts in Stent Industry Tuesday, 6 May 2008 | 7:40 PM ET
    Heart Stent

    Too few influential doctors are telling the public if they have financial ties to the companies that make lifesaving drug-coated stents.

  • Merck "Adapts" To Tredaptive Setback Tuesday, 29 Apr 2008 | 11:37 AM ET

    Investors are finding no solace in Merck's reaffirmation that it'll still hit its earnings numbers this year. Instead they're punishing the stock after the company announced what everyone is calling a surprise and a significant setback.

  • Merck Shares Plunge as Cholesterol Drug Rejected Tuesday, 29 Apr 2008 | 11:20 AM ET
    Merck

    U.S. health regulators have rejected a new drug from Merck that was designed to raise the level of HDL, or "good" cholesterol, the company said, sending its shares plunging more than 10 percent.

  • Regulatory "Risky Business" for Pharma & Biotech Monday, 28 Apr 2008 | 11:56 AM ET
    Risky Business

    It's a big day for pipeline progress...or not. Late Friday, Merck and Schering-Plough announced that the Food and Drug Administration won't approve their combo Claritin-Singulair combo pill for allergies.

  • Wyeth Profit Slips, but Tops Wall Street Estimates Tuesday, 22 Apr 2008 | 7:22 AM ET

    Wyeth Tuesday said its first-quarter net profit fell slightly, hurt by the sudden launch early this year of a generic form of its Protonix ulcer drug, but surprisingly strong sales enabled the company to beat Wall Street profit forecasts.

  • Abbott Profit Rises, Boosted by Prescriptions Wednesday, 16 Apr 2008 | 7:51 AM ET

    Abbott Laboratories said Wednesday first-quarter earnings increased 34 percent on higher sales of its prescription drugs and medical devices and favorable foreign exchange factors.

  • Johnson & Johnson's Earnings And Its Very "Taxing" Day Tuesday, 15 Apr 2008 | 3:56 PM ET
    Johnson & Johnson

    Dow component and healthcare conglomerate (drugs, consumer products, medical devices) Johnson & Johnson beat and boosted. That's Wall Street jargon for earnings coming in higher than expectations and the guidance for the rest of the year being raised. So, why did the stock go down?

  • The Week:  Saving the Worst For Last Saturday, 12 Apr 2008 | 7:31 AM ET
    Stocks down

    A steady stream of downbeat news seemed to leave the market unmoved for most of the week -- until the bluest of the blue chips, General Electric, posted first-quarter earnings that missed Wall Street expectations by seven cents per share, and lowered its full-year guidance.  

  • Week Ahead: Challenging -- At The Least Friday, 11 Apr 2008 | 7:34 PM ET

    A double helping of economic data and first-quarter earnings reports will flood the zone next week, but it's the corporate earnings that will drive stocks and give a better picture of where the economy is going. If GE's bombshell earnings miss is an indicator, the news will be as nasty as traders expect.

  • Japan's Takeda to Buy Millennium Pharma Thursday, 10 Apr 2008 | 6:25 AM ET

    Takeda Pharmaceutical said it would buy U.S. firm Millennium Pharmaceuticals for $8.8 billion to boost its cancer drug business, in the biggest overseas acquisition by a Japanese drug maker.

  • Defensive Stock Picks for a Rebound Monday, 7 Apr 2008 | 1:22 PM ET

    After a rough start, top investment officers are looking for gradual improvement as 2008 goes on.  Harbor Advisory's Jack DeGan is among them, and he won't sugar-coat the current situation.

  • Stocks End on High Note But Quarter Is Sour Monday, 31 Mar 2008 | 5:17 PM ET

    Stocks advanced Monday, led by financials, as the market looked for insight into the second quarter and braced for closing its worst quarter in 5 1/2 years.

  • Financials Lead Rebound; Merck Skids Monday, 31 Mar 2008 | 2:16 PM ET

    Stocks advanced Monday, led by financials, as the market looked for insight into the second quarter and braced for closing its worst quarter in 5 1/2 years.

  • Drug Stock Scorecard: MRK, SGP Losers--Pfizer A Winner Monday, 31 Mar 2008 | 11:35 AM ET

    Who’s the winner and loser in drug stocks today? Schering-Plough down 25 percent (!) and Merck down 16 percent pre-open on a study that showed that the companies cholesterol lowering drugs Vytorin and Zetia were not more effective than less expensive drugs.

  • Market-Moving Murmurs Thursday, 27 Mar 2008 | 6:30 PM ET

    The American College Of Cardiology kicks off its annual meeting in Chicago on Saturday. What’s the trade ahead of this major meeting of heart doctors?

  • J&J, Boston Scientific, Medtronic & Abbott: Stent "Stuff" Thursday, 27 Mar 2008 | 10:50 AM ET
    Heart Stent

    Ahead of the world's biggest gathering of cardiologists in Chicago this weekend, there's a flurry of news about stents--the expensive little wire mesh tubes that prop open clogged arteries. First, the Food and Drug Administration has posted new proposed guidelines for pre-and post-market testing of the controversial devices.

  • Lightning Round: Bear Stearns, Disney, Costco and More Thursday, 6 Mar 2008 | 7:23 PM ET

    Cramer makes the call on viewers' favorite stocks.